Published in New England Journal of Medicine · View the paper (DOI)
The ESCAPE-TRD study found that esketamine nasal spray outperforms quetiapine in treating treatment-resistant major depression, with patients showing higher remission rates and reduced depressive symptoms. The results suggest esketamine as a safe and effective treatment option for those with treatment-resistant depression.
Coverage from 2 institutions